Galecto (GLTO) Stock Price, News & Analysis

Company Overview

Galecto Inc. is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders. In addition, Galecto is advancing a LOXL2 inhibitor, GB2064, in preclinical studies aimed at addressing unmet needs in hepatic and systemic fibrosis. These molecules leverage targeted delivery and selective inhibition strategies to modulate the fibrotic cascade and the tumor microenvironment.

Founded in 2012, Galecto is headquartered in Copenhagen, Denmark, with research and development operations in Cambridge, Massachusetts. The company’s leadership team brings together expertise in molecular biology, medicinal chemistry and clinical development, with board members and executives drawn from both academia and the pharmaceutical industry. Galecto collaborates with academic centers and industry partners to advance its pipeline and explore additional indications for its proprietary inhibitors.

Key Stats

• Today's Range: $9.51 to $10.57
• 50-Day Range: $2.58 to $17.92
• 52-Week Range: $2.01 to $31.70
• Volume: 89,585 shs
• Average Volume: 7.63 million shs
• Market Capitalization: $12.65 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Galecto Stock Analysis - MarketRank™

Galecto scored higher than 14% of companies evaluated by MarketBeat, and ranked 869th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Galecto.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Galecto are expected to grow in the coming year, from ($15.91) to ($13.54) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Galecto is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Galecto is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Galecto has a P/B Ratio of 0.87. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.31% of the float of Galecto has been sold short.

Short Interest Ratio / Days to Cover

Galecto has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Galecto has recently increased by 57.69%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Galecto does not currently pay a dividend.

Dividend Growth

Galecto does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.31% of the float of Galecto has been sold short.

Short Interest Ratio / Days to Cover

Galecto has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Galecto has recently increased by 57.69%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: -0.33

News Sentiment

Galecto has a news sentiment score of -0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Galecto this week, compared to 0 articles on an average week.

Search Interest

24 people have searched for GLTO on MarketBeat in the last 30 days.

MarketBeat Follows

5 people have added Galecto to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Galecto insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.80% of the stock of Galecto is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 14.20% of the stock of Galecto is held by institutions.

GLTO Stock Analysis - Frequently Asked Questions

How have GLTO shares performed this year?

Galecto's stock was trading at $4.65 at the beginning of the year. Since then, GLTO shares have increased by 106.0% and is now trading at $9.58.

How were Galecto's earnings last quarter?

Galecto, Inc. (NASDAQ:GLTO) posted its earnings results on Tuesday, August, 5th. The company reported ($2.60) earnings per share for the quarter.

When did Galecto's stock split?

Shares of Galecto reverse split on the morning of Friday, August 30th 2024.The 1-25 reverse split was announced on Wednesday, August 28th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did Galecto IPO?

Galecto (GLTO) raised $86 million in an initial public offering on Thursday, October 29th 2020. The company issued 5,700,000 shares at $14.00-$16.00 per share. BofA Securities, SVB Leerink and Credit Suisse acted as the underwriters for the IPO and Kempen & Co. was co-manager.

How do I buy shares of Galecto?

Shares of GLTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Galecto own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Galecto investors own include Medical Properties Trust (MPW), Realty Income (O), Oxford Square Capital (OXSQ), Plug Power (PLUG), AGNC Investment (AGNC), Aberdeen Total Dynamic Dividend Fund (AOD) and Abrdn Global Infrastructure Income Fund (ASGI).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 10/18/2025
• Next Earnings (Estimated): 11/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GLTO
• CIK: 1800315
• Web: galecto.com
• Phone: 45-7070-5210
• Fax: N/A
• Employees: 40
• Year Founded: 2011

Profitability

• EPS (Trailing Twelve Months): ($13.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.44 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -115.70%
• Return on Assets: -95.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.96
• Quick Ratio: 4.96

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.99 per share
• Price / Book: 0.87

Miscellaneous

• Outstanding Shares: 1,320,000
• Free Float: 1,182,000
• Market Cap: $12.65 million
• Optionable: Optionable
• Beta: 1.38